Jemma Smith — Novartis

Client Experience

Novartis

Pharmaceutical & Healthcare

Senior creative experience across multiple Novartis brands, shaping and delivering creative across HCP, patient and internal communications, from integrated campaigns and digital through to presentations and wider brand materials.

Scroll

Brands

A closer look at the individual Novartis brands worked on, and the creative delivered for each.

View work

Cosentyx

Conference leaflet, symposium deck, pull-up banner

View work

Leqvio

Primary & secondary care CVA iPad tools, pull-up banner, BCS presentation

View work

Kesimpta

Leavepiece, A5 flyer and interactive PDF on iPad

Cosentyx

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, front cover

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, pages 2 and 3

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, pages 4 and 5

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, pages 6 and 7

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, pages 8 and 9

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, pages 10 and 11

Cosentyx · Conference Leaflet Cosentyx BAD Annual Conference 2025 leaflet, back cover

Cosentyx · Symposium Deck Cosentyx BAD symposium deck on screen, slide 1: Celebrating 10 years of Innovation in Dermatology

Cosentyx · Symposium Deck Cosentyx BAD symposium deck on screen, slide 2: speaker panel

Cosentyx · Symposium Deck Cosentyx BAD symposium deck on screen, slide 3: housekeeping

Cosentyx · Symposium Deck Cosentyx BAD symposium deck on screen, slide 4: UK-approved indications and dosing

Cosentyx · Banner

Cosentyx pull-up banner for the BAD Annual Conference symposium

01 / 12

Leqvio

Leqvio · Primary Care CVA Leqvio primary care iPad tool, home screen

Leqvio · Primary Care CVA Leqvio primary care iPad tool, Malik patient journey timeline

Leqvio · Primary Care CVA Leqvio primary care iPad tool, early and sustained lipid-lowering data screen

Leqvio · Primary Care CVA Leqvio primary care iPad tool, non-HDL-C outcomes data screen

Leqvio · Primary Care CVA Leqvio primary care iPad tool, long-term LDL-C exposure and CHD risk data screen

Leqvio · Banner

Leqvio · Secondary Care CVA Leqvio secondary care iPad tool, home screen

Leqvio · Secondary Care CVA Leqvio secondary care iPad tool, Hazel patient journey timeline

Leqvio · Secondary Care CVA Leqvio secondary care iPad tool, Aaron patient journey modal

Leqvio · Secondary Care CVA Leqvio secondary care iPad tool, early and sustained lipid-lowering data screen

Leqvio · Secondary Care CVA Leqvio secondary care iPad tool, LDL-C exposure and cardiovascular risk data screen

Leqvio · Secondary Care CVA Leqvio secondary care iPad tool, ESC/EAS targets in secondary CVD prevention screen

Leqvio · BCS Presentation Leqvio BCS Annual Conference presentation on screen, slide 1: Moving from intervention to prevention, a road map to success

Leqvio BCS Annual Conference presentation on screen, slide 1: Moving from intervention to prevention, a road map to success

Leqvio · BCS Presentation Leqvio BCS Annual Conference presentation on screen, slide 2: speaker disclosures

Leqvio · BCS Presentation Leqvio BCS Annual Conference presentation on screen, slide 3: known pathophysiological mechanisms of cardiovascular risk

Leqvio BCS Annual Conference presentation on screen, slide 3: known pathophysiological mechanisms of cardiovascular risk

Leqvio · BCS Presentation Leqvio BCS Annual Conference presentation on screen, slide 4: targeting the at-risk population

Leqvio · BCS Presentation Leqvio BCS Annual Conference presentation on screen, slide 5: target population, social deprivation and comorbidities

Leqvio BCS Annual Conference presentation on screen, slide 5: target population, social deprivation and comorbidities

01 / 17

Kesimpta

Kesimpta · Leavepiece Kesimpta digital landing page on iPad, home: Efficacy profile you can trust

Kesimpta · Leavepiece Kesimpta digital landing page on iPad, do not miss the early treatment window in RRMS

Kesimpta · Leavepiece Kesimpta digital landing page on iPad, efficacy demonstrated for up to 6 years in ASCLEPIOS I/II and ALITHIOS

Kesimpta · Leavepiece Kesimpta digital landing page on iPad, near-complete suppression of MRI lesion activity up to 6 years

Kesimpta · Leavepiece Kesimpta digital landing page on iPad, NEDA-3 outcomes at Year 6

Kesimpta · Flyer Kesimpta A5 flyer, front cover: Efficacy profile you can trust

Kesimpta · Flyer Kesimpta A5 flyer, inside spread: efficacy and disease activity data

Kesimpta · Flyer Kesimpta A5 flyer, back cover: safety profile

Kesimpta · Interactive PDF Kesimpta specialist commentary iPad deck, cover: clinical and patient burden in multiple sclerosis service provision

Kesimpta specialist commentary iPad deck, cover: clinical and patient burden in multiple sclerosis service provision

Kesimpta · Interactive PDF Kesimpta specialist commentary iPad deck, the patient burden of MS

Kesimpta · Interactive PDF Kesimpta specialist commentary iPad deck, the clinical and cost burden of MS

Kesimpta · Interactive PDF Kesimpta specialist commentary iPad deck, current service provision challenges in MS

Kesimpta · Interactive PDF Kesimpta specialist commentary iPad deck, the changing environment for MS service provision

Kesimpta · Interactive PDF Kesimpta specialist commentary iPad deck, DMTs: a revolution in MS management

01 / 14